1451-P: Associations between Circulating PCSK9 and ANGPTL3, ANGPTL8, and APOA5 in a Population-Based Cohort: Insights into Lipid Metabolism and Cardiometabolic Risk
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1451-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von MOHAMMAD QADDOUMI und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: PCSK9 is a central regulator of LDL receptor metabolism, but emerging evidence suggests it may also influence triglyceride-rich lipoproteins via interaction with angiopoietin-like proteins and apolipoproteins. This study evaluates associations between PCSK9 and ANGPTL3, ANGPTL8, and ApoA5 in a well-characterized population cohort. Our objective is to assess the relationship between circulating PCSK9 and ANGPTL3, ANGPTL8, and ApoA5, and to explore how their levels vary across PCSK9 quartiles.
Methods
Data from 1,501 adults were analysed. PCSK9 levels were stratified into quartiles and log-transformed for analysis. Associations were assessed using partial correlation and multivariable log-log regression adjusted for age, sex, BMI, and diabetes status. Quartile trends were evaluated using Kruskal-Wallis tests and Spearman correlations.
Results
ANGPTL3 showed a significant positive association with PCSK9 (partial r = 0.270, p < 0.001; β = 0.224, 95% CI: 0.1815-0.2665). Median ANGPTL3 levels increased by 30.2% from Q1 to Q4 (KW p < 0.001). ANGPTL8 also exhibited a strong positive association (partial r = 0.264, p < 0.001; β = 0.195, 95% CI: 0.1611-0.2293), with a 39.7% increase across quartiles (KW p < 0.001). ApoA5 was inversely correlated with PCSK9 (partial r = -0.099, p < 0.001; β = -0.075, 95% CI: -0.1102 to -0.0398) and decreased by 8.4% across quartiles (KW p = 0.0103). All associations remained statistically significant after correction for multiple comparisons (FDR < 0.001).
Conclusion
Circulating PCSK9 is positively associated with ANGPTL3 and ANGPTL8 and inversely associated with ApoA5. These findings support a broader role for PCSK9 in triglyceride metabolism, suggesting novel metabolic interactions relevant to diabetes and cardiometabolic risk beyond LDL-C regulation. Disclosure M. Qaddoumi: None. J.A. Abubaker: None. A.M. Channanath: None. M. Abdul-Ghani: None. F. Al-Mulla: None. N. Seidah: None. M. Abu-Farha: None. Funding Kuwait Foundation for the Advancement of Sciences (RA-2019-30)
Zitieren
APA
QADDOUMI, M., ABUBAKER, J. A., CHANNANATH, A. M., ABDUL-GHANI, M., AL-MULLA, F., SEIDAH, N., & ABU-FARHA, M. (2026). 1451-P: Associations between Circulating PCSK9 and ANGPTL3, ANGPTL8, and APOA5 in a Population-Based Cohort: Insights into Lipid Metabolism and Cardiometabolic Risk. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1451-p
Vancouver
QADDOUMI M, ABUBAKER JA, CHANNANATH AM, ABDUL-GHANI M, AL-MULLA F, SEIDAH N, et al. 1451-P: Associations between Circulating PCSK9 and ANGPTL3, ANGPTL8, and APOA5 in a Population-Based Cohort: Insights into Lipid Metabolism and Cardiometabolic Risk. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1451-p
BibTeX
@article{QADDOUMI2026,
author = {QADDOUMI, MOHAMMAD and ABUBAKER, JEHAD A. and CHANNANATH, ARSHAD M. and ABDUL-GHANI, MUHAMMAD and AL-MULLA, FAHD and SEIDAH, NABIL and ABU-FARHA, MOHAMED},
title = {1451-P: Associations between Circulating PCSK9 and ANGPTL3, ANGPTL8, and APOA5 in a Population-Based Cohort: Insights into Lipid Metabolism and Cardiometabolic Risk},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1451-p}
}
EUVIMED